AIV Logo AIV Assistant

Loading...

 Logo Veru Inc. - VERU Open Veru Inc. in new tab

3.01
P/E
0.69
EPS
6.00
P/B
3.94
ROE
-1.06
Beta
-0.74

3.0100

3.010

Daily: -14.00%
Key Metrics

Earnings date: Dec. 15, 2025

P/E: 0.69

EPS: 6.00

Book Value: 1.05

Price to Book: 3.94

Debt/Equity: 21.21

% Insiders: 0.142%

Growth

Revenue Growth: 0.18%

Estimates

Forward P/E: -14.21

Forward EPS: -0.29

 Logo About Veru Inc. - (VERU)

Country: United States

Sector: Health Care

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion